HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CI 951

structure given in first source

Also Known As:

CI-951

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - CI 951: 2

Experts

1.	Adeoye, Opeolu M: 1 article (10/2013)
2.	Bonomo, Jordan B: 1 article (10/2013)
3.	Ficker, David M: 1 article (10/2013)
4.	Hart, Kimberly W: 1 article (10/2013)
5.	Keegan, Shaun P: 1 article (10/2013)
6.	Knight, William A: 1 article (10/2013)
7.	Lindsell, Christopher J: 1 article (10/2013)
8.	Privitera, Michael D: 1 article (10/2013)
9.	Szaflarski, Jerzy P: 1 article (10/2013)

Related Diseases

1.	Seizures (Absence Seizure) 10/01/2013 - "9/11 patients with seizures died during hospitalization, compared with 11/22 patients without seizures (82% vs. 50%; difference 32%, CI 951%-63%). "
2.	Ischemia 01/01/1990 - "Twenty minutes after MCA occlusion, CI-951 was administered at 0.5 microgram/kg/min and brain pHi and CBF were determined in both regions of severe and moderate ischemia for 4 h postocclusion. "
3.	Brain Ischemia (Cerebral Ischemia) 01/01/1990 - "CI-951 may be a useful therapeutic agent for focal cerebral ischemia if histological and outcome studies verify these data." 01/01/1990 - "The novel dihydronaphthyridine Ca2+ channel blocker CI-951 improves CBF, brain pHi, and EEG recovery in focal cerebral ischemia." 01/01/1990 - "The effects of the novel dihydronaphthyridine Ca2+ antagonist CI-951 on focal cerebral ischemia were assessed during MCA occlusion in 30 white New Zealand rabbits under 1.0% halothane anesthesia. "

Related Drugs and Biologics

1.	Halothane (Fluothane)

Related Therapies and Procedures

1.	Anesthesia